Literature DB >> 25785102

Surgical procedure and long-term survival of hilar cholangiocarcinoma.

Yue Wang1, Helen Yang2, Chunjian Shen3, Ji Luo4.   

Abstract

OBJECTIVE: The aim of this study was to identify the influencing factors related to outcome of patients with hilar cholangiocarcinoma.
METHODS: From January 1999 to January 2009, 204 cases of hilar cholangiocarcinoma undergoing surgery were analyzed retrospectively. Bismuth-Corlette classification showed type I in 18 patients, type II in 40, type IIIa in 65, type IIIb in 54, type IV in 27. Survival analysis was performed by the Kaplan-Meier method and the relationship between each of the clinicopathologic variables and survival was assessed by the log-rank test. Multivatiate results were confirmed using Cox regression.
RESULTS: Radical resection was accomplished in 161 of 204 patients (78.9%). Radical resection offered the best chance of long-term survival, with the 1-, 3-, and 5-year survival rate were 62.6%, 42.4%, 23.7%, respectively. Univariate analysis showed that lymph node metastasis, surgical margin, operative procedure and tumor differentiation were prognostic impacts. The difference was statistically significant (P < 0.05). Cox multivariate analysis showed that lymph node metastasis and surgical margin are two separate prognostic factors.
CONCLUSION: Racical resection is the key to improve the long-term survival rate of hilar cholangiocarcinoma and a favorable outcome after resection is mainly determined by curative resection and the absence of lymph node metastasis.

Entities:  

Keywords:  Cholangiocarcinoma; prognosis; survival

Year:  2015        PMID: 25785102      PMCID: PMC4358557     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

1.  Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma.

Authors:  Michael F Gerhards; Thomas M van Gulik; Dioniso González González; Erik A J Rauws; Dirk J Gouma
Journal:  World J Surg       Date:  2003-02       Impact factor: 3.352

2.  Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.

Authors:  Michael A Hughes; Deborah A Frassica; Charles J Yeo; Taylor S Riall; Keith D Lillemoe; John L Cameron; Ross C Donehower; Daniel A Laheru; Ralph H Hruban; Ross A Abrams
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-02-02       Impact factor: 7.038

3.  Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience.

Authors:  Y Nimura; J Kamiya; S Kondo; M Nagino; K Uesaka; K Oda; T Sano; H Yamamoto; N Hayakawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

4.  Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Naru Kondo; Ryutaro Sakabe; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-10-14       Impact factor: 5.344

5.  Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroyuki Nakamura; Akira Nakashima; Taijiro Sueda
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

6.  Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.

Authors:  Tadahiro Takada; Hodaka Amano; Hideki Yasuda; Yuji Nimura; Takashi Matsushiro; Hiroyuki Kato; Takukazu Nagakawa; Toshimichi Nakayama
Journal:  Cancer       Date:  2002-10-15       Impact factor: 6.860

7.  Wedge resection of the portal bifurcation concomitant with left hepatectomy plus biliary reconstruction for hepatobiliary cancer.

Authors:  Satoshi Kondo; Hiroyuki Katoh; Satoshi Hirano; Yoshiyasu Ambo; Eiichi Tanaka; You Kawarada; Mitsuhito Kaji; Setsuyuki Ohtake; Shunichi Okushiba; Toshiaki Morikawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  2002

8.  Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.

Authors:  Sung Gyu Lee; Gi Won Song; Shin Hwang; Tae Yong Ha; Deok Bog Moon; Dong Hwan Jung; Ki Hun Kim; Chul Soo Ahn; Myung Hwan Kim; Sung Koo Lee; Kyu Bo Sung; Gi Young Ko
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-23       Impact factor: 7.027

9.  Role of liver transplantation in the treatment of unresectable liver cancer.

Authors:  R Pichlmayr; A Weimann; K J Oldhafer; H J Schlitt; J Klempnauer; A Bornscheuer; A Chavan; E Schmoll; H Lang; G Tusch
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

Review 10.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

View more
  5 in total

Review 1.  Perioperative Management of Hilar Cholangiocarcinoma.

Authors:  Katherine E Poruk; Timothy M Pawlik; Matthew J Weiss
Journal:  J Gastrointest Surg       Date:  2015-05-29       Impact factor: 3.452

2.  Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma.

Authors:  Hai-Jie Hu; Rong-Xing Zhou; Anuj Shrestha; Yong-Qiong Tan; Wen-Jie Ma; Qin Yang; Jiong Lu; Jun-Ke Wang; Yong Zhou; Fu-Yu Li
Journal:  Oncotarget       Date:  2017-10-23

3.  Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?

Authors:  Jun-Ke Wang; Hai-Jie Hu; Anuj Shrestha; Wen-Jie Ma; Qin Yang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  Oncotarget       Date:  2017-07-11

4.  Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma.

Authors:  Yu Wang; Wei Cui; Wenzhe Fan; Yingqiang Zhang; Wang Yao; Kunbo Huang; Jiaping Li
Journal:  Oncotarget       Date:  2016-08-16

Review 5.  The role of tumour microenvironment: a new vision for cholangiocarcinoma.

Authors:  Ziyan Chen; Pengyi Guo; Xiaozai Xie; Haitao Yu; Yi Wang; Gang Chen
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.